Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71

Key Points

• This analysis aims to determine how prior oral anticoagulation experience influences bleeding risk in patients treated with the factor XI inhibitor abelacimab.
• Prespecified analysis from AZALEA-TIMI 71 trial
• Patients with atrial fibrillation
• Assessment of bleeding risk associated with abelacimab in relation to prior anticoagulation experience
• Abelacimab reduced bleeding consistently across different prior anticoagulation experiences.
• Greater absolute benefit noted among patients who were OAC-naïve.
• NCT04755283 for trial registration.